Latest Regenerative Medicine News

Page 3 of 8
Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.
Ada Torres
Ada Torres
16 Jan 2026
Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.
Ada Torres
Ada Torres
16 Jan 2026
Osteopore Limited has completed the full subscription of Tranche 1 under its A$20 million convertible notes facility, raising an additional A$250,000 to support ongoing business and future projects.
Ada Torres
Ada Torres
14 Jan 2026
Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.
Ada Torres
Ada Torres
6 Jan 2026
Orthocell has reached a significant milestone with 100 units of its nerve repair product Remplir™ sold in the US, signaling accelerating adoption in a $1.6 billion market. The company’s strategic medical education and distributor network are driving momentum ahead of further hospital approvals.
Ada Torres
Ada Torres
18 Dec 2025
Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.
Ada Torres
Ada Torres
15 Dec 2025
Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.
Ada Torres
Ada Torres
15 Dec 2025
Osteopore Limited has drawn an additional A$250,000 under the first tranche of its redeemable convertible notes, continuing its steady capital raise to support growth and innovation.
Ada Torres
Ada Torres
25 Nov 2025
Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.
Ada Torres
Ada Torres
25 Nov 2025
Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.
Ada Torres
Ada Torres
24 Nov 2025
Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.
Ada Torres
Ada Torres
5 Nov 2025
Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.
Ada Torres
Ada Torres
31 Oct 2025